Use of the diabetes drug metformin before a diagnosis of Covid-19 is associated with a threefold decrease in mortality in Covid-19 patients with Type-2 diabetes, a new study suggests."Since similar results have now been obtained in .
PORTLAND, Ore., Jan. 14, 2021 /PRNewswire/ Cambia Health Foundation announces the seventh cohort of scholars accepted into its Sojourns® Scholar Leadership Program. Twelve emerging palliative care leaders were carefully chosen through a rigorous selection process from a highly competitive pool. In addition, the Foundation has opened the 2021 Sojourns® Scholar Leadership Program Call for Applications and encourages palliative care professionals from across the country, including all disciplines and practice settings to apply.
ADVERTISEMENT
The Sojourns Scholar Leadership Program is designed to identify, cultivate and advance the next generation of palliative care leaders. As part of the leadership program, each Sojourns Scholar receives $180,000 in funding ($90,000/year over a two-year period) to conduct an innovative and impactful clinical, policy, educational, health equity or systems change project in the field of palliative care. Scholars also participate with other scholars
Metformin use reduces risk of death for patients with COVID greekherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from greekherald.com Daily Mail and Mail on Sunday newspapers.
Jeremy Blackburn joined the Department of Computer Science at Binghamton University in fall 2019. Jeremy is broadly interested in data science, with a focus on large-scale measurements and modeling. His largest line of work is in understanding jerks on the Internet. His research into understanding toxic behavior, hate speech, and fringe and extremist Web communities has been covered in the press by The Washington Post, the New York Times, The Atlantic, The Wall Street Journal, the BBC and New Scientist, among others.
Prior to his appointment at Binghamton, Jeremy was an assistant professor in the Department of Computer Science at the University of Alabama at Birmingham. Prior to that, Jeremy was an associate researcher at Telefonica research in Barcelona, Spain.
Credit: UAB
BIRMINGHAM, Ala. - Use of the diabetes drug metformin before a diagnosis of COVID-19 is associated with a threefold decrease in mortality in COVID-19 patients with Type 2 diabetes, according to a racially diverse study at the University of Alabama at Birmingham. Diabetes is a significant comorbidity for COVID-19. This beneficial effect remained, even after correcting for age, sex, race, obesity, and hypertension or chronic kidney disease and heart failure, said Anath Shalev, M.D., director of UAB s Comprehensive Diabetes Center and leader of the study. Since similar results have now been obtained in different populations from around the world including China, France and a UnitedHealthcare analysis this suggests that the observed reduction in mortality risk associated with metformin use in subjects with Type 2 diabetes and COVID-19 might be generalizable, Shalev said.